Thursday, 11 August 2022

Heidelberg Pharma inks deal worth € 105 M with Japan's Chiome Bioscience

18 July 2022 | News

For the development of an antibody drug conjugate

Image credit: shutterstock

Image credit: shutterstock

Heidelberg Pharma AG and Japan-based Chiome Bioscience have announced the signing of an exclusive, target-specific research and option agreement. Heidelberg Pharma Research GmbH signed this collaboration, which will combine one of Chiome’s monoclonal antibodies against one specific target with Heidelberg Pharma’s proprietary ATACplatform.

Under the terms of the agreement, Chiome will have access to Heidelberg Pharma’s Amanitin toxin-linker platform technology and has an option for an exclusive, target-specific license for global development and commercialization rights to the product candidate resulting from the research collaboration.

Heidelberg Pharma would be eligible to receive an option fee, development- and sales-related milestone payments of up to 105 million Euro as well as tiered royalties in the mid-upper single digit range.

Sign up for the editor pick and get articles like this delivered right to your inbox.

Editors Pick
+Country Code-Phone Number(xxx-xxxxxxx)


× Your session has been expired. Please click here to Sign-in or Sign-up
   New User? Create Account